Company intelligence / Profile preview

ExoMas S.A.

Ownership: Private
Development stage: Other

Overview

ExoMas S.A. is a preclinical-stage biotech company developing native neural stem cell exosome formulations to prevent and treat neurodegenerative diseases. The company has demonstrated significant results in animal models for Parkinson’s disease and traumatic brain injury. It was recently selected by the Eretz.bio biohealth accelerator at Albert Einstein Hospital in São Paulo, Brazil.

Therapeutic areas: Neurology
Modalities: Native neural stem cell exosomes
Industry: Biotech

Drug pipeline

1 asset

CBSD-EXO

Preclinical

Partnerships

Eretz.bio biohealth accelerator at Albert Einstein Hospital, São Paulo, Brazil

Beyond the preview

Go deeper on ExoMas S.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoMas S.A..